New immune boost for rare immune disorder? small trial underway

NCT ID NCT07076446

Completed Disease control Sponsor: CSL Behring Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 17, 2026 · Updated 3 times

Summary

This study tests a drug called IgPro20, a type of immune globulin given under the skin, in adults with primary immunodeficiency who have never received such treatment. The goal is to see how the drug moves through the body and whether it is safe. Only 8 participants are enrolled, making this a very early look at the therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IgPro20 (immune globulin subcutaneous, 20% liquid)
What this could lead to: If successful, this could provide a new treatment option for people with primary immunodeficiency who have not previously received immune globulin therapy.
What could go wrong: This is a very small, early-phase study with only 8 participants, so results may not apply to everyone. Side effects like infusion reactions or infections are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY IMMUNODEFICIENCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

inborn error of immunity Primary Immunodeficiency Diseases

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY IMMUNODEFICIENCY

Contacts and locations

Locations

Allergy & Clinical Immunology

Pittsburgh, Pennsylvania, 15241, United States
Allergy, Asthma and Clinical Research Center

Oklahoma City, Oklahoma, 73120, United States
Immunoe Health Centers

Centennial, Colorado, 80112, United States
Johns Hopkins Bayview Medical Center

Baltimore, Maryland, 21224, United States
Medical Research of Arizona

Scottsdale, Arizona, 85251, United States
Midwest Immunology

Plymouth, Minnesota, 55446, United States
Research Solutions of AZ

Litchfield Park, Arizona, 85340, United States
Washington University

St Louis, Missouri, 63141, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.